Application

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97503720

Filing Date: 07/14/2022

To the Commissioner for Trademarks:

MARK: GENERATIVE BIOLOGY (Standard Characters, see below )

The literal element of the mark consists of GENERATIVE BIOLOGY. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Generate Biomedicines, Inc., a corporation of Delaware, having an address of
      55 Cambridge Parkway, Suite 800E
      Cambridge, Massachusetts 02142
      United States
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 001:  Biological and chemical agents for scientific and research use
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 005:  Pharmaceutical preparations for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders, but excluding DNA-based gene therapy; therapeutic agents for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders but excluding DNA-based gene therapy; therapeutic products for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders, but excluding DNA-based gene therapy
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.



The owner's/holder's proposed attorney information: Christina M. Licursi. Other appointed attorneys are Michael A. Albert, Nicole Davis Amar, Michael J. Attisha, C. Hunter Baker, Jason W. Balich, Melissa Beede, Brandon S. Blackwell, Joseph M. Bowler, Kady S. Bruce, David F. Cauble, Tani Chen, Gitanjali Chimalakonda, Thomas S. Chlebeck, Aya Cieslak-Tochigi, Bryan S. Conley, Gregory F. Corbett, William L. Czaplyski, Cara B. Dawson, Elizabeth A. DiMarco, Heather J. DiPietrantonio, Matthew O. Duffey, Stuart V. Duncan Smith, Roque El-Hayek, Neil P. Ferraro, Emma L. Frank, Thomas A. Franklin, Susmita A. Gadre, Edward R. Gates, Jean Ge, David S. Gesner, Richard F. Giunta, Matthew H. Grady, Patricia L. Granahan, Eric P. Greenwald, Blaine M. Hackman, Philip J. Hamzik, James M. Hanifin, Jr., John S. Harmon, Jason M. Honeyman, Gerald B. Hrycyszyn, Jeffrey D. Hsi, Elisabeth H. Hunt, Robert E. Hunt, Daniel M. Huttle, Robert A. Jensen, Marc S. Johannes, Oona M. Johnstone, Quincy L. Kayton, Hunter D. Keeton, Alexandra K. Kim, Jessamine M. Lee, Kevin Y. Li, Christina M. Licursi, Helen C. Lockhart, Chelsea Loughran, Yue Matthew Ma, Kevin MacDonald, Robert T. Maldonado, John L. Marquardt, Kira-Khanh McCarthy, William R. McClellan, Gabriel J. McCool, Marie A. McKiernan, Michele Moresco, James H. Morris, Elizabeth S. Mulski, Gregory S. Nieberg, Michelle K. Nyein, Timothy J. Oyer, Zachary P. Piccolomini, Michael J. Pomianek, Curtis R. Powell, Randy J. Pritzker, Stephen S. Rabinowitz, Michael N. Rader, Suresh Rav, Laura B. Rogers, Jonathan B. Roses, Daniel G. Rudoy, Edward J. Russavage, Eric J. Rutt, Robert N. Sahr, Anant K. Saraswat, Turhan F. Sarwar, Tonia A. Sayour, Claire E. Schuster, Amanda Slade, Nathan R. Speed, Charles T. Steenburg, Charlotte R. Stewart-Sloan, John L. Strand, Shirley Tan, Andrew J. Tibbetts, Maria A. Trevisan, Michael J. Twomey, John R. Van Amsterdam, Ryan M. Van Olst, Amanda L. Varrichione, Janice A. Vatland, Jessica A. vonReyn, Robert H. Walat, Patrick R.H. Waller, Edmund J. Walsh, Jennifer J. Wang, Daniel T. Wehner, John L. Welch, Adam R. Wichman, Andrew W. Williams, Chelsea E. Witte-Garcia, Douglas R. Wolf, Jie Ziang, Daniel W. Young, Lock See Yu-Jahnes, Adam Z. Zeiger, William Wei Zhang, Norman H. Zivin. Christina M. Licursi of Wolf, Greenfield & Sacks, P.C., is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      600 Atlantic Avenue
      Boston, Massachusetts 02210
      United States
      617-646-8000(phone)
      617-646-8646(fax)
      cxltrademarks@wolfgreenfield.com
The docket/reference number is F08292000501.
Christina M. Licursi submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:

Christina M. Licursi

PRIMARY EMAIL FOR CORRESPONDENCE: cxltrademarks@wolfgreenfield.com       SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $700 has been submitted with the application, representing payment for 2 class(es).

Declaration

Declaration Signature
The attached signature image file:
\\TICRS\EXPORT18\IMAGEOUT18\975\037\97503720\xml1\APP0003.JPG



Signatory's Name: Sean Martin
Signatory's Position: Chief Legal Officer, General Counsel
Signatory's Phone Number: Not Provided
Signature method: Handwritten
Payment Sale Number: 97503720
Payment Accounting Date: 07/14/2022

Serial Number: 97503720
Internet Transmission Date: Thu Jul 14 16:40:15 ET 2022
TEAS Stamp: USPTO/BAS-XXX.XX.XXX.XXX-202207141640150
25912-97503720-820d51fe6a19276b424243abc
da4653433c30109066feaabf29c366fea23f1d5b
2b-CC-40130921-20220714162036353064